News

Our scientists to speak at the SCI-2024 – XXVIII National Congress

We are honored to have two senior scientists speaking at the SCI-2024 – XXVIII National Congress in Milan. Elena Ardini: Wednesday, August 28th    8:30am – 9:00am Discovery of entrectinib: an amazing journey from target biology to innovative therapy (KN-028) ParallelTopic04: Health          Location: Blue1 (level +1) Barbara Valsasina and Gianfranco Pasut,  (Dept. Pharmaceutical and Pharmacological Sciences, University of Padova) […]

We are speaking at the 3rd GLOBAL XDC INNOVATION CONFERENCE in WuXi (CHINA)!

We are speaking at the 3rd GLOBAL XDC INNOVATION CONFERENCE in WuXi (CHINA) partnering event in WuXi (CHINA) , 10 – 12 Sep. 2024 We look forward to your presence to explore future partnership opportunities. * * * * * Contact: Valsasina Barbara : Barbara.Valsasina@demo111.axxiem.com Lupi Rosita: rosita.lupi@demo111.axxiem.com * * * * * About NMS […]

Nerviano Medical Sciences announces FDA protocol clearance of new IND application for NMS-812, a first-in-class dual inhibitor of PERK/GCN2. Brian Sherer, PhD. appointed to lead and accelerate the development.

NMS-812: A clinical phase potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the integrated stress response (ISR)   The United States Food and Drug Administration (FDA) has cleared the protocol for new investigational new drug (IND) application for NMS-812, a first-in-class orally bioavailable and highly potent small molecule dual inhibitor of PERK/GCN2.   NMS […]

Nerviano Medical Sciences announces strategic portfolio shaping.

NERVIANO, IT and BOSTON, Mass, June 21 , 2024 – Nerviano Medical Sciences S.r.l. (“NMS” or the “Company”), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, […]

Nerviano Medical Sciences S.r.l. announced new Board of Directors and Statutory Auditors

NERVIANO, 28, May 2024_Nerviano Medical Sciences S.r.l. (NMS), a wholly owned subsidiary of NMS Group S.p.A, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced, following the shareholder resolution dated 13 May 2024, changes to the Board of Directors and Statutory Auditors of the holding company […]

Share this page

Facebook
Twitter
LinkedIn
Email
svg.e-font-icon-svg {display:none!important} .elementor-button-icon {display:none!important} .show-more, .show-more2 {display:none!important} img.pf-large-image.pf-primary-img.flex-width.pf-size-full.blockImage { display: none!important; }